# Manganese modulates hepatocellular carcinoma cytotoxicity and doxorubicin sensitivity in a dose dependent manner

**Authors:** Hao-lun Wang, Qian-qing Fan, Ting Tang, Zi-yun He, Yu-an Xie, Zhi-hui Liu

PMC · DOI: 10.3389/fonc.2026.1715702 · Frontiers in Oncology · 2026-02-13

## TL;DR

This study shows that manganese affects liver cancer cell survival and drug response in a dose-dependent way, with low doses increasing resistance and high doses triggering cell death pathways.

## Contribution

The novel finding is that manganese concentration modulates HCC cell sensitivity to doxorubicin and activates distinct molecular pathways depending on dose.

## Key findings

- Low MnCl2 concentrations enhance doxorubicin resistance by increasing AKT pathway phosphorylation.
- High MnCl2 concentrations activate P53 and immune response pathways while downregulating mitosis and MYC pathways.
- Manganese's dose-dependent effects on HCC cells suggest potential therapeutic applications.

## Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally, characterized by decreased manganese (Mn) levels in tumor tissues compared to noncancerous liver tissues. Although manganese’s role in enhancing immune responses and inhibiting tumor growth has been noted, its specific contribution to HCC development and its influence on drug sensitivity are not well defined.

We assessed the viability of HCC cells treated with various concentrations of MnCl2 using assays such as CCK-8, EdU staining, and flow cytometry. These assays revealed that MnCl2 at different concentrations could reduce doxorubicin sensitivity or induce cytotoxicity. Subsequently, transcriptome sequencing was employed to identify differentially expressed genes and those playing critical roles. The potential molecular mechanisms were investigated through functional enrichment analysis, and key genes were validated using Western blot (WB) analysis.

Our study found that low MnCl2 concentrations increased AKT pathway phosphorylation, enhancing doxorubicin resistance, while high MnCl2 concentrations activated the P53 pathway and immune response, downregulating mitosis and the MYC pathway.

This research elucidates the impact of Mn²+ concentration on HCC cell behavior, offering a theoretical basis for Mn²+’s potential use in HCC treatment. The findings contribute to a deeper understanding of Mn²+’s role in HCC and may inform future therapeutic strategies.

## Linked entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], TP53 (tumor protein p53) [NCBI Gene 7157], MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609]
- **Chemicals:** manganese (PubChem CID 23930), MnCl2 (PubChem CID 24480), doxorubicin (PubChem CID 31703)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** OR2A7 (olfactory receptor family 2 subfamily A member 7) [NCBI Gene 401427] {aka HSDJ0798C17, OR2A21}, RPL10A (ribosomal protein L10a) [NCBI Gene 4736] {aka CSA19, Csa-19, L10A, NEDD6, uL1}, TAPBP (TAP binding protein) [NCBI Gene 6892] {aka MHC1D3, NGS17, TAPA, TPN, TPSN}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, IFIT1 (interferon induced protein with tetratricopeptide repeats 1) [NCBI Gene 3434] {aka C56, G10P1, IFI-56, IFI-56K, IFI56, IFIT-1}, RPL35 (ribosomal protein L35) [NCBI Gene 11224] {aka DBA19, L35, uL29}, JAK2 (Janus kinase 2) [NCBI Gene 374199] {aka JAK-2}, ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636] {aka G1P2, IFI15, IMD38, IP17, UCRP, hUCRP}, GBP3 (guanylate binding protein 3) [NCBI Gene 2635], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, RPS11 (ribosomal protein S11) [NCBI Gene 6205] {aka S11, uS17}, ABCB6 (ATP binding cassette subfamily B member 6 (LAN blood group)) [NCBI Gene 10058] {aka ABC, LAN, MTABC3, PRP, umat}, ACACB (acetyl-CoA carboxylase beta) [NCBI Gene 32] {aka ACACbeta, ACC-beta, ACC2, ACCB, ACCbeta, HACC275}, RPS14 (ribosomal protein S14) [NCBI Gene 6208] {aka EMTB, S14, uS11}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, RPL23A (ribosomal protein L23a) [NCBI Gene 6147] {aka L23A, MDA20, uL23}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, OAS1 (2'-5'-oligoadenylate synthetase 1) [NCBI Gene 4938] {aka E18/E16, IFI-4, IMD100, OIAS, OIASI}, SLC13A5 (solute carrier family 13 member 5) [NCBI Gene 284111] {aka DEE25, EIEE25, INDY, NACT, mIndy}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, SAT1 (spermidine/spermine N1-acetyltransferase 1) [NCBI Gene 6303] {aka DC21, KFSD, KFSDX, SAT, SSAT, SSAT-1}, Cort (cortistatin) [NCBI Gene 12854] {aka CST, PCST}, OAS2 (2'-5'-oligoadenylate synthetase 2) [NCBI Gene 4939] {aka AIAISD2}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374] {aka CPT I, CPT1, CPT1-L, CPTI-L, L-CPT1}, DDIT4 (DNA damage inducible transcript 4) [NCBI Gene 54541] {aka Dig2, REDD-1, REDD1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, RPS28 (ribosomal protein S28) [NCBI Gene 6234] {aka DBA15, S28, eS28}, IFIT2 (interferon induced protein with tetratricopeptide repeats 2) [NCBI Gene 3433] {aka G10P2, GARG-39, IFI-54, IFI-54K, IFI54, IFIT-2}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, IFI35 (interferon induced protein 35) [NCBI Gene 3430] {aka IFP35}, PSMB9 (proteasome 20S subunit beta 9) [NCBI Gene 5698] {aka LMP2, PRAAS3, PRAAS6, PSMB6i, RING12, beta1i}, MYO6 (myosin VI) [NCBI Gene 4646] {aka DFNA22, DFNB37}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}, PSMB8 (proteasome 20S subunit beta 8) [NCBI Gene 5696] {aka ALDD, D6S216, D6S216E, JMP, LMP7, NKJO}, RPL32 (ribosomal protein L32) [NCBI Gene 6161] {aka L32, PP9932, eL32}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, RPS26 (ribosomal protein S26) [NCBI Gene 6231] {aka DBA10, S26, eS26}, ISG20 (interferon stimulated exonuclease gene 20) [NCBI Gene 3669] {aka CD25, HEM45}, HMGCS1 (3-hydroxy-3-methylglutaryl-CoA synthase 1) [NCBI Gene 3157] {aka CMYO28, HMGCS}, HLA-E (major histocompatibility complex, class I, E) [NCBI Gene 3133] {aka HLA-6.2, QA1}, RPL38 (ribosomal protein L38) [NCBI Gene 6169] {aka L38, eL38}, RPL18 (ribosomal protein L18) [NCBI Gene 6141] {aka DBA18, L18, eL18}, ACACA (acetyl-CoA carboxylase alpha) [NCBI Gene 31] {aka ACAC, ACACAD, ACACalpha, ACC, ACC1, ACCA}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, CHAC1 (ChaC glutathione specific gamma-glutamylcyclotransferase 1) [NCBI Gene 79094], CALR (calreticulin) [NCBI Gene 811] {aka CALR1, CRT, HEL-S-99n, RO, SSA, cC1qR}, LPIN3 (lipin 3) [NCBI Gene 64900] {aka LIPN3L, SMP2, dJ620E11.2}, RPL13A (ribosomal protein L13a) [NCBI Gene 23521] {aka L13A, TSTA1, uL13}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, IFITM3 (interferon induced transmembrane protein 3) [NCBI Gene 10410] {aka 1-8U, DSPA2b, IP15}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}
- **Diseases:** neuroinflammation (MESH:D000090862), hepatoblastoma (MESH:D018197), cytotoxic (MESH:D064420), Huntington disease (MESH:D006816), lung damage (MESH:D008171), Cancer (MESH:D009369), Alzheimer's disease (MESH:D000544), non-alcoholic fatty liver disease (MESH:D065626), neurotoxicity (MESH:D020258), lung cancer (MESH:D008175), Parkinson's disease (MESH:D010300), multidrug (MESH:D018088), viral (MESH:D014777), alcoholism (MESH:D000437), diabetic cardiomyopathy (MESH:D058065), amyotrophic lateral sclerosis (MESH:D000690), metastasis (MESH:D009362), neurodegeneration (MESH:D019636), HL (MESH:C538324), inflammation (MESH:D007249), hypoxia (MESH:D000860), liver tumor (MESH:D008113), systemic lupus erythematosus (MESH:D008180), primary immunodeficiency (MESH:D000081207), neurological disorders (MESH:D009461), Hepatocellular carcinoma (MESH:D006528), carcinogenesis (MESH:D063646), hypoxic (MESH:D002534), breast cancer (MESH:D001943), prion disease (MESH:D017096), neuronal damage (MESH:D009410), Mn (MESH:D020149)
- **Chemicals:** streptomycin (MESH:D013307), polyacrylamide (MESH:C016679), fatty acid (MESH:D005227), EDTA (MESH:D004492), heme (MESH:D006418), nitrogen (MESH:D009584), oxygen (MESH:D010100), penicillin (MESH:D010406), adriamycin (MESH:D004317), mannose (MESH:D008358), Chinese herbal medicine (-), platinum (MESH:D010984), ROS (MESH:D017382), Manganese (MESH:D008345), DAPI (MESH:C007293), cholesterol (MESH:D002784), sorafenib (MESH:D000077157), PVDF (MESH:C024865), MnCl2 (MESH:C025340), SDS (MESH:D012967), EdU (MESH:C022811), TRIzol (MESH:C411644), lipid (MESH:D008055), CO2 (MESH:D002245), fructose (MESH:D005632), CCK-8 (MESH:D012844)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Gallus gallus (bantam, species) [taxon 9031]
- **Cell lines:** Huh7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336), HepG2.2.15 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_L855), NCI-60 — Homo sapiens (Human), Lung small cell carcinoma, Cancer cell line (CVCL_A592), MIHA — Homo sapiens (Human), Transformed cell line (CVCL_SA11)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946836/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946836/full.md

## References

69 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946836/full.md

---
Source: https://tomesphere.com/paper/PMC12946836